167 related articles for article (PubMed ID: 38094038)
21. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
Lee YP; Jeong BH; Eun Y; Kang CI; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Eur J Cancer; 2021 Dec; 159():167-173. PubMed ID: 34753013
[TBL] [Abstract][Full Text] [Related]
22. Pralsetinib for the treatment of non-small cell lung cancer.
Fu XY; Dong XD; Zeng L; Ashby CR; Chen ZS; Cheng C
Drugs Today (Barc); 2021 Sep; 57(9):559-569. PubMed ID: 34586104
[TBL] [Abstract][Full Text] [Related]
23. Salvage Therapy With Selpercatinib for
d'Arienzo PD; Cunningham N; O'Sullivan H; Grieco C; Patel V; Popat S
JTO Clin Res Rep; 2023 Dec; 4(12):100581. PubMed ID: 38034820
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
Ke JY; Huang S; Jing ZT; Duan MC
Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
[TBL] [Abstract][Full Text] [Related]
25. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
Gu L; Ji W; Xu Y; Han Y; Jian H
Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
[TBL] [Abstract][Full Text] [Related]
26. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
[TBL] [Abstract][Full Text] [Related]
27. RET Inhibitors in Non-Small-Cell Lung Cancer.
Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
[TBL] [Abstract][Full Text] [Related]
28. Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
Locantore P; Novizio R; Corsello A; Paragliola RM; Pontecorvi A; Corsello SM
Expert Opin Drug Discov; 2022 Feb; 17(2):101-107. PubMed ID: 34702125
[TBL] [Abstract][Full Text] [Related]
29. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
30. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
[TBL] [Abstract][Full Text] [Related]
31. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
32.
Zhang T; Wang H; Cai Z; Zhang S; Jiang C
Front Oncol; 2023; 13():1078076. PubMed ID: 37139148
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance.
Trocchianesi S; Po A; Citarella A; Spinello Z; Rughetti A; Besharat ZM; Autilio TM; Pecce V; Verrienti A; Elisei R; Durante C; Catanzaro G; Ferretti E
Biomed Pharmacother; 2023 Aug; 164():114995. PubMed ID: 37301138
[TBL] [Abstract][Full Text] [Related]
34. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
36. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
[TBL] [Abstract][Full Text] [Related]
37. Advances in the treatment of RET-fusion-positive lung cancer.
Pall G; Gautschi O
Lung Cancer; 2021 Jun; 156():136-139. PubMed ID: 33933276
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
Front Oncol; 2021; 11():704084. PubMed ID: 34497761
[TBL] [Abstract][Full Text] [Related]
39. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S; Califano R; Reinmuth N; Tamma A; Puri T
Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
[TBL] [Abstract][Full Text] [Related]
40. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
